Pharma: Back to the future... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Back to the future...

Jul 10, 2006

Pharma stocks were at the receiving end in the recent meltdown witnessed in the Indian stockmarkets. We, however, continue to believe that FY07 will be the inflection point for pharma companies and will set the growth path for the future after the difficult past couple of years. With pharma companies slated to announce 1QFY07 results in July, we shall analyse major factors that are likely to influence the full year (FY07) performance. The growth drivers will be...

The domestic market: The domestic pharma market is expected to grow in higher single digits in FY07, largely led by growth in the existing products of pharma companies. Most of the pharma majors with their strong product portfolio are expected to grow above the industry growth rate. In terms of new product launches, in-licensing products will play a critical growth in driving the topline. Besides, MNC pharma majors have begun to launch products from their parents' folio (case in point Glaxo and Pfizer), which have started contributing to the topline, albeit in a small way. However, investors should note that it would be a while before these products start making a significant contribution.

Generics: As we have mentioned in earlier articles, the generics industry is expected to witness a revival with a large number of drugs going off patent in the US generics market. Besides Para III launches (drugs launched on Day 1 of patent expiry), there have been successes on the Para IV front as well (cases in point: Dr.Reddy's (for 'Simvastatin' and 'Proscar') and Ranbaxy (for 'Simvastatin 80 mg'). In addition, companies such as Cipla (which is partnering with global generic majors) will also stand to benefit immensely as the demand for bulk drugs starts picking pace on the back of a rise in ANDA approvals. These positive developments coupled with the contribution from the fast growing semi regulated markets of Russia, Africa, Asia and the Middle East are expected to significantly augment the revenue streams of pharma companies catering to the generics market.

Acquisitions: FY06 was the year in which Indian pharma companies embarked on the inorganic route to acquire companies and establish a presence in the global markets. The efforts on this front will be reflected in the FY07 results of these companies. Notable examples include Dr. Reddy's acquisition of Betapharm (Germany), Ranbaxy's acquisition of Terapia (Romania) and Nicholas Piramal's acquisition of Avecia and Morpeth (both in the UK). Since most of these acquisitions were made in the latter half of FY06, the full year impact of the same will start flowing in from FY07 onwards. Besides, this year could possibly see more such acquisitions taking place as Ranbaxy, Dr. Reddy's, Wockhardt and Nicholas Piramal have clearly outlined inorganic growth as part of their strategy in the future.

The margin story: While we expect margins as a whole to improve for companies under our coverage, the extent of improvement will depend upon the various business models adopted by these companies. For MNC pharma companies, the key will be improved product mix, reduced dependence on drugs under the DPCO control and cost efficiencies at the operating level. For domestic companies, the pricing pressure hampering margins will have to be offset by a continuous flow of products to the markets.

However, concerns still remain...

Pricing pressure: The pricing pressure in the US generics market has till now shown no real signs of abating. With the rise in patent expiries, the competition has also intensified, which is expected to pressurise the performance of generic companies. Even in FY07, with a rise in the number of patent expiries, prices could erode by as much as 90% on Day 1 itself (excluding the 180-day exclusivities). Therefore, besides a continuous flow of product launches, efforts made to diversify into other countries outside the US will be a positive move, which will enable companies to negate the impact of the highly competitive US market.

Regulatory issues: Regulatory issues remain an area of concern both in India and abroad. In India, the threat of the new drug pricing policy to bring 354 essential drugs under price control looms like a dark cloud over the sector. Since, the policy has yet to be announced, it will be difficult to guage the exact impact of the same. While MNC pharma companies will stand to lose out, domestic pharma companies will also likely feel the pinch if this policy gets introduced. Abroad, the attractiveness of the German generics market could get slightly blunted with the new drug policy in the country making 30% price cuts mandatory for generic drugs.

Investment in pharma stocks...
While growth is visible in most of the pharma companies under our coverage, valuations will be the key factor to watch out for. After the carnage witnessed on the Indian bourses during the last week of May, we believe that valuations of certain pharma stocks look reasonable at the current juncture. As such, we advise investors to adopt a stock-specific investment strategy while investing in the sector.

Equitymaster requests your view! Post a comment on "Pharma: Back to the future...". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Dec 3, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS